lcalvobartolome/proxann_data huggingface dataset:
Topic: Health — R&D
Subject: Health
Date: 2014-09-15 00:00:00

Family Asthma Act - Amends the Public Health Service Act to require the Director of the Centers for Disease Control and Prevention (CDC) to collaborate with state and local health departments to: (1) conduct activities regarding asthma, including deterring the harmful consequences of uncontrolled asthma, and disseminating health education and information regarding prevention of asthma episodes and strategies for managing asthma; and (2) develop state plans incorporating public health responses to reduce the burden of asthma, particularly regarding disproportionately affected populations.

 Revises and expands requirements for asthma surveillance activities.

 Requires the Director to coordinate data collection activities to maximize the comparability of results.

Requires the Secretary of Health and Human Services (HHS) to submit an assessment of current activities related to asthma prevention, management and surveillance along with recommendations for the future direction of asthma activities.
Topic: Health — R&D
Subject: Health
Date: 2014-09-17 00:00:00

Reducing Disparities Using Care Models and Education Act of 2014 - Requires the Secretary of Health and Human Services (HHS) to contract with the Institute of Medicine to study health disparities, existing programs and policies intended to reduce disparities, and priorities for, and expansion of, programs targeting disparities.

Requires the Secretary to develop guidelines for entities to develop and implement programs to reduce health disparities. Directs the Secretary to incorporate these guidelines into HHS activities.

Authorizes the Secretary to award grants for programs to reduce health disparities.

Requires the Innovation Center of the Centers for Medicare and Medicaid Services (CMS) to test a payment and service delivery model that includes incentives for reducing health disparities.
Topic: Health — R&D
Subject: Health
Date: 2014-09-18 00:00:00

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2014 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome.

Requires the Director to develop a system to collect data on Tourette syndrome, including epidemiological information, primary data, and data on the availability of medical and social services for individuals with Tourette syndrome and their families.

 Requires the Director to award grants and contracts to public or nonprofit private entities to support four to six Collaborative Research Centers for Tourette Syndrome in different regions to conduct basic and clinical research on Tourette syndrome.

 Requires the Director to award grants for research on the full range of symptoms within the Tourette syndrome clinical spectrum and the efficacy of treatment options for particular patient subpopulations.

Requires the Director to designate a portion of the amounts made available to carry out NIH programs and activities for a fiscal year to carry out programs and activities with respect to Tourette syndrome.
Topic: Health — R&D
Subject: Health
Date: 2014-11-12 00:00:00

(This measure has not been amended since it was introduced. The expanded summary of the Senate reported version is repeated here.)

Adding Ebola to the FDA Priority Review Voucher Program Act - (Sec. 2) Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.)

Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS).

Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times.

Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.
Topic: Health — R&D
Subject: Health
Date: 2014-12-11 00:00:00

Dormant Therapies Act of 2014 - Requires the Department of Health and Human Services (HHS) to designate medicines being, or intended to be, investigated to address unmet medical needs as dormant therapies. Gives a dormant therapy a 15-year protection period during which no drug can be approved by relying on the approval of the dormant therapy absent a right of reference from the holder of the approved application for the dormant therapy.

Requires the sponsor of a potential dormant therapy to have a clinical plan to investigate the medicine and intend to file an application for approval or licensure of the medicine as a new drug or biological product. Prohibits the active moiety of the medicine from being the same as an active moiety in a drug or highly similar to one in a biological product for which an application has been submitted.

Requires the sponsor of a potential dormant therapy to list their patents that apply to the medicine and waive rights to those patents at the end of the dormant therapy protection period if the medicine is approved.

Allows a sponsor to withdraw a dormant therapy designation request unless the medicine has been approved or licensed.

Entitles the sponsor of a dormant therapy to extend patents that apply to the medicine to the end of the protection period.

Prohibits a dormant therapy from receiving specified protections that apply to pediatric, infectious disease, or rare disease or condition medicines.

Directs HHS to require a sponsor to certify that the clinical plan for a dormant therapy has been completed and that approval was based on investigations in the clinical plan.
Topic: Health — R&D
Subject: Health
Date: 2015-01-06 00:00:00

(This measure has not been amended since it was introduced. The summary of that version is repeated here.)

Low-Dose Radiation Research Act of 2015

Requires the Director of the Department of Energy (DOE) Office of Science to carry out a research program on low dose radiation to enhance the scientific understanding of and reduce uncertainties associated with the effects of exposure to low dose radiation.

Requires the Director to enter into an agreement with the National Academies to conduct a study assessing the current status and development of a long-term strategy for low dose radiation research.

Requires such study to:

 identify current scientific challenges for understanding the long-term effects of ionizing radiation, assess the status of current low dose radiation research, formulate overall scientific goals for the future of low-dose radiation research, recommend a long-term strategic and prioritized research agenda to address scientific research goals for overcoming the identified scientific challenges in coordination with other research efforts, define the essential components of a research program that would address this research agenda within the universities and the National Laboratories, and assess the effectiveness of such a program. Directs the Secretary of Energy to deliver to Congress a five-year research plan that responds to the study's findings and recommendations and identifies and prioritizes research needs.

Makes DOE's limitation on human research inapplicable to research under this Act.
Topic: Health — R&D
Subject: Health
Date: 2015-01-06 00:00:00

Triple-Negative Breast Cancer Research and Education Act of 2015

Requires the National Institutes of Health to expand, intensify, and coordinate programs for the conduct and support of research on triple-negative breast cancer (breast cancers whose cells are negative for estrogen receptors, progesterone receptors, and the HER2 protein).

Directs the Centers for Disease Control and Prevention to develop and disseminate to the public information regarding triple-negative breast cancer, including information on: (1) the incidence and prevalence of triple-negative breast cancer among women, (2) the elevated risk for minority women, and (3) the availability of a range of treatment options.

Requires the Health Resources and Services Administration to develop and disseminate information on triple-negative breast cancer to health care providers.
Topic: Health — R&D
Subject: Health
Date: 2015-01-08 00:00:00

Ensuring Access to Clinical Trials Act of 2015 

This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.
Topic: Health — R&D
Subject: Health
Date: 2015-01-13 00:00:00

Advancing Research for Neurological Diseases Act of 2015

Amends the Public Health Service Act to require the Centers for Disease Control and Prevention to: (1) enhance and expand infrastructure and activities to track the epidemiology of neurological diseases, including multiple sclerosis and Parkinson's disease; and (2) incorporate information obtained through those activities into a National Neurological Diseases Surveillance System. Requires the Department of Health and Human Services (HHS) to ensure that the System facilitates further research on neurological diseases.

Requires HHS to provide for the collection and storage of information on neurological diseases, including the incidence, prevalence, and other information, to the extent practicable.

Requires HHS to: (1) make information and analysis in the System available to federal agencies and to the public, including researchers; and (2) ensure that privacy and security protections applicable to the System are at least as stringent as the protections under the Health Insurance Portability and Accountability Act.
Topic: Health — R&D
Subject: Armed forces and national security
Date: 2015-01-21 00:00:00

Expanding Care for Veterans Act

Directs the Secretary of Veterans Affairs (VA) to develop a plan to expand the scope of VA's research and education on, and delivery and integration of, complementary and alternative medicine services.

Requires the Secretary to carry out, through VA's Office of Patient Centered Care and Cultural Transformation, a three-year program to: (1) assess the feasibility and advisability of integrating the delivery of complementary and alternative medicine services selected by the Secretary with other VA health care services for veterans, and (2) identify and resolve barriers to providing such services and integrating them with other VA health services.

Requires such program to be conducted, at not fewer than 15 VA medical centers, by integrating the provision of complementary and alternative medicine services with other VA health care services provided to veterans who have a mental health condition, experience chronic pain, or have a chronic condition. Requires veterans' participation to be voluntary.

Directs the Secretary to contract with a qualified independent entity for comprehensive studies of the barriers encountered by veterans in receiving, and by administrators and clinicians in providing, complementary and alternative medicine services through VA. Provides for the conduct of such studies through surveys of veterans and VA administrators and clinicians.

Requires the Secretary to carry out a three-year program awarding grants to public or private nonprofit entities to assess the feasibility and advisability of using wellness programs to complement the provision of mental health care to veterans and family members who are eligible for readjustment counseling from VA.
Topic: Health — R&D
Subject: Health
Date: 2015-01-26 00:00:00

Accelerating Biomedical Research Act 

This bill amends the Balanced Budget and Emergency Deficit Control Act of 1985 to require certain adjustments to discretionary spending limits in FY2016-FY2021 to accommodate increases in appropriations to the National Institutes of Health at the Department of Health and Human Services.
Topic: Health — R&D
Subject: Health
Date: 2015-01-28 00:00:00

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2015

Amends the Public Health Service Act to require the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome.

Requires the NIH to develop a system to collect data on Tourette syndrome, including epidemiological information, primary data, and data on the availability of medical and social services for individuals with Tourette syndrome and their families.

 Requires the NIH to award grants and contracts to public or nonprofit private entities to support four to six Collaborative Research Centers for Tourette Syndrome in different regions to conduct basic and clinical research on Tourette syndrome.

 Requires the NIH to award grants for research on the full range of symptoms within the Tourette syndrome clinical spectrum and the efficacy of treatment options for particular patient subpopulations.

Requires the NIH to designate a portion of the amounts made available to carry out NIH programs and activities for a fiscal year to carry out programs and activities with respect to Tourette syndrome.
Topic: Health — R&D
Subject: Health
Date: 2015-02-04 00:00:00

Medical Innovation Act of 2015

This bill amends the Public Health Service Act to require certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH).

A drug manufacturer with over $1 billion in net income in a fiscal year that has entered into a settlement agreement in the previous five years with a federal agency regarding specified violations must pay 1% of its net income to the Department of Health and Human Services (HHS) for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research, including a drug for which a patent contains information that relates to, or is based upon, federally-funded research.

Each fiscal year, HHS must publish a list of manufacturers that make payments, each manufacturer's covered blockbuster drugs, and payment amounts.

Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year.

The FDA's priority use for payments must include advancing regulatory science for medical products.

The NIH's priority use for payments must include supporting: (1) research that fosters radical innovation, (2) research that advances fundamental knowledge, (3) research related to diseases that disproportionately account for federal health care spending, and (4) early career scientists.

A covered blockbuster drug for which a manufacturer has not made a required payment is considered misbranded and cannot be sold until payment is made.
Topic: Health — R&D
Subject: Health
Date: 2015-02-05 00:00:00

Permanent Investment in Health Research Act of 2015 

This bill amends the Public Health Service Act to make appropriations to the National Institutes of Health (NIH) for FY2016-FY2025:

 for FY2016, $32 billion; and for each fiscal year from FY2017-FY2025, the amount appropriated for the preceding fiscal year, adjusted by any percentage increase in nominal gross domestic product during the preceding calendar year. The bill amends the Balanced Budget and Emergency Deficit Control Act of 1985 (Gramm-Rudman-Hollings Act) to add NIH to the list of programs and activities exempt from sequestration. Sequestration is a process of automatic, usually across-the-board spending reductions under which budgetary resources are permanently cancelled to enforce specific budget policy goals.
Topic: Health — R&D
Subject: Health
Date: 2015-02-05 00:00:00

Tick-Borne Disease Research Accountability and Transparency Act of 2015

Amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to conduct or support epidemiological, basic, translational, and clinical research regarding Lyme disease and other tick-borne diseases.

Directs HHS to establish the Interagency Lyme and Tick-Borne Disease Working Group to review all HHS efforts concerning tick-borne diseases to ensure interagency coordination and examine research priorities. Requires the Working Group to: (1) provide a summary of tick-borne disease research, advances, and scientific viewpoints every two years; (2) make recommendations to HHS regarding tick-borne disease activities; and (3) hold annual public meetings.

Requires HHS to submit a strategic plan for tick-borne disease research within three years of enactment and every five years thereafter that includes: (1) budgetary requirements; (2) benchmarks for improving tick-borne disease diagnosis, treatment, outcomes, and prevention; and (3) a plan to disseminate Working Group summaries and other relevant information on tick-borne disease to health professionals and the public.
Topic: Health — R&D
Subject: Health
Date: 2015-02-05 00:00:00

Expanding the Availability of Medicare Data Act 

Expands the kinds of uses of Medicare data available to qualified entities for quality and patient care improvement activities.

(A "qualified entity" is a public or private entity that: [1] is qualified to use claims data to evaluate the performance of service providers and suppliers on measures of quality, efficiency, effectiveness, and resource use; and [2] agrees to meet specified requirements, such as ensuring data security.) Authorizes a qualified entity to use claims data combined with non-claims data the entity has received, as well as information derived from evaluation of service provider and supplier performance, to conduct additional non-public analyses and provide or sell them to authorized users for non-public use (including to assist service providers and suppliers to develop and participate in quality and patient care improvement activities, including new models of care).

Defines "authorized users" as service providers, suppliers, employers, health insurance issuers, medical societies or hospital associations, or any other entities approved by the Secretary of Health and Human Services.

Prohibits a qualified entity from charging a fee to provide Medicare claims data.

Requires a qualified entity and an authorized user to enter into a data use agreement, and prohibits the use of data or analyses for marketing purposes or, except in certain circumstances, its redisclosure.

Directs the Secretary to provide Medicare data to qualified clinical data registries for purposes of linking it with clinical outcomes data and performing risk-adjusted, scientifically valid analyses and research to support quality improvement or patient safety. Requires charging a fee to a registry for such data.

Amends title XVIII (Medicare) of the Social Security Act (SSAct) to include among standardized extracts of Medicare claims data that may be made available to qualified entities, if the Secretary determines appropriate, also claims data under SSAct titles XIX (Medicaid) and XXI (State Children's Health Insurance) (CHIP).

Requires any fees charged for making standardized extracts available to qualified entities to be deposited into the Centers for Medicare & Medicaid Services Program Management Account (currently, into the Federal Supplementary Medical Insurance Trust Fund).
Topic: Health — R&D
Subject: Health
Date: 2015-02-13 00:00:00

Facilitating Participation in Clinical Data Registries Act of 2015

This bill requires the Office for Human Research Protections of the Department of Health and Human Services to issue guidance within one year on the application of the Common Rule, which provides protections for human research subjects, to clinical data registries.
Topic: Health — R&D
Subject: Health
Date: 2015-03-02 00:00:00

Accelerating the End of Breast Cancer Act of 2015

Directs the President to establish the Commission to Accelerate the End of Breast Cancer to help end breast cancer by January 1, 2020.

Directs the Commission to: (1) identify opportunities and ideas within government and the private sector that are key components in achieving the end of breast cancer and which have been overlooked, yet are ripe for collaboration and investment; (2) recommend projects to leverage such opportunities and ideas in the areas of the primary prevention of breast cancer and the causes and prevention of breast cancer metastasis; and (3) ensure that its activities are coordinated with, and do not duplicate the efforts of, programs and laboratories of other government agencies.

Directs the President to enter into an agreement with the Institute of Medicine for an evaluation of the Commission's progress.

Terminates the Commission on June 1, 2020.
Topic: Health — R&D
Subject: Economics and public finance
Date: 2015-03-13 00:00:00

America's Fund for Future Opportunities and Outcomes in the United States Act of 2015 or the America's FOCUS Act of 2015

Establishes a separate account in the U.S. Treasury to be known as the America's FOCUS Fund, into which shall be deposited: (1) revenue generated by civil and criminal fines and penalties for violations or alleged violations of federal law; (2) revenue generated by legal settlements reached between corporations and the federal government for violations or alleged violations of federal law; and (3) gifts, bequests, or donations to the Fund from private entities or individuals.

Requires that, of the total revenue in the Fund: (1) up to 33% be used to award grants for youth mentoring and science, technology, engineering, and mathematics (STEM) education; (2) up to 33% be used to award grants for justice reinvestment; (3) up to 33% be used to award grants and prizes for innovations in medical research and development; and (4) the remaining revenue be used to reduce the federal budget deficit or, if there is no deficit, to reduce the federal debt.

Directs the Secretary of Education to award the grants for youth mentoring programs, and the Associate Administrator for Education for the National Aeronautics and Space Administration (NASA) to award the grants for STEM education programs, to: (1) national non-profit, community-based organizations with at least two years of experience in administering such programs; and (2) state or local governments.

Requires that, of the funds available for justice reinvestment, the Department of Justice (DOJ): (1) award 50% to state and local governments for justice reinvestment projects, (2) use up to 25% of the funds to support federal justice reinvestment projects, and (3) allocate up to 25% of the funds to grant programs established under the Second Chance Act within DOJ.

Requires the Director of the National Institutes of Health to use the revenue designated for medical innovation to fund entities that conduct innovative medical research and development. Authorizes the Director to use up to 15% of those funds to award monetary prizes to entities that have used their own funding and research facilities to produce innovative results.

Requires that the grant funds be used to supplement, not supplant, other federal, state, and local funds designated to carry out those activities.